Phaseline

Companies › Aqualung Therapeutics

Aqualung Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALT-100 mAb
Monoclonal antibody mechanism not specified
–Phase 2Acute Respiratory Distress Syndrome (ARDS)May 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05938036ALT-100 mAbPhase 2Acute Respiratory Distress Syndrome (ARDS)RespiratoryMay 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Connect Biopharm Upstream Bio PPD Development, LP Shanghai Mabgeek Biotech.Co.Ltd Uniquity One (UNI)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.